• Aptevo Therapeutics reported updated interim results from its ongoing RAINIER study of mipletamig in frontline acute myeloid leukemia, with trial completion and Phase 2 dose selection targeted by end-2026.
• Results have already been presented in the update, showing broad clinical activity with a high rate of remission in patients treated with mipletamig alongside standard therapy.
• Safety profile appeared differentiated versus similar immune-oncology approaches, with no cytokine release syndrome reported in frontline patients in the dataset.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605130805ACCESSWRNAPR_____1166364) on May 13, 2026, and is solely responsible for the information contained therein.